for the Dual Antiplatelet Therapy (DAPT) Study Investigators IMPORTANCE Early cardiovascular and bleeding events after coronary stenting are associated with high risk of morbidity and mortality.
lated to atherosclerosis progression and thrombosis in stented and nonstented coronary arteries persists indefinitely, despite treatment and risk factor modification. 3, 4 Antiplatelet medications, including aspirin and P2Y 12 inhibitors, have become the standard of care as they decrease the risk of myocardial infarction (MI) and stent thrombosis (ST) within the first year after PCI. 5, 6 While recent randomized trials [7] [8] [9] have shown the benefits of treatment beyond 1 year, these findings have been counterbalanced by risks of bleeding, which are of particular concern with long-term therapy.
Although the prognosis following early ischemic and bleeding events has been well described, 4, [10] [11] [12] data for events occurring beyond 1 year after PCI are limited. 13 This scarcity may result from smaller size and duration of PCI trials, [14] [15] [16] while larger observational studies often lack systematic follow-up or independent event adjudication. 11, 12 We sought to assess the cumulative incidence of death after ischemic and bleeding events occurring among patients in the Dual Antiplatelet Therapy (DAPT) Study beyond 1 year after coronary stenting.
Methods

Study Population
The DAPT Study (described previously 8, 17 ) was a randomized, double-blind trial comparing 12 vs 30 months of dual antiplatelet therapy in individuals undergoing PCI with a drug-eluting stent or a bare metal stent. The study involved 220 US and international clinical sites from 11 countries. After coronary stenting, 25 682 enrolled patients older than 18 years were prescribed thienopyridine plus aspirin therapy for 12 months. At 12 months, treatment-adherent patients who had no major adverse cardiovascular or cerebrovascular events, recurrent revascularization, or moderate or severe bleeding continued taking aspirin and were randomized to continued thienopyridine therapy vs placebo for 18 additional months. Randomized treatment was then discontinued, and patients were followed up for 3 additional months while receiving aspirin therapy alone. During the 21-month postrandomization period, all potential cardiovascular and bleeding events were adjudicated by a clinical events committee masked to treatment assignment. This study was conducted in accordance with the Declaration of Helsinki. The institutional review board at each institution approved the study, and all participating patients provided written informed consent. For the present secondary analysis, we examined all 11 648 randomized individuals.
Outcomes and Exposures
The primary outcome was death at 21 months after randomization (33 months after coronary stenting 
Statistical Analysis
Categorical variables were reported as counts and percentages, and continuous variables were reported as means (SDs). Between-group differences were assessed using Fisher exact test or χ 2 test for categorical variables and t test or Wilcoxon rank sum test for continuous variables. Among the randomized study population, we examined (1) the rate of ischemic and bleeding events after randomization, (2) the mortality risk among patients with each of these events, and (3) the cumulative incidence of mortality after each event. Patients experiencing multiple ischemic and bleeding events contributed data to both the ischemic events group and the bleeding events group; however, for patients with more than one of the same type of event, only the earliest event was included. We used Kaplan-Meier methods to estimate the cumulative incidence of death after an ischemic or bleeding event among those experiencing these events. Follow-up started at the time of the event and continued until death or study completion. Patients who died on the same day as the event were included in the analysis. To quantify the total population at risk of death after an event, we used Kaplan-Meier methods to estimate the cumulative incidence of death after the event among all randomized patients, with follow-up starting at the time of randomization.
Cox proportional hazards regression models with timedependent covariates for exposure status were created for each Patients with ischemic events had a higher prevalence of cardiovascular risk factors and prior cardiovascular disease ( Table 1) . They also more often initially presented with non-ST-segment elevation MI, had smaller minimum stent diameters, and received more paclitaxel-eluting stents ( Table 2) . Patients with ischemic events were more often randomized to placebo (283 patients [59.2%]) than to continued thienopyridine therapy (195 patients [40.8%]) (P < .01).
The median follow-up time after an ischemic event was 275.0 days (interquartile range [IQR] , 90.0-456.0 days). Among the 478 patients with ischemic events, 52 (10.9%) died, and 41 deaths (78.8%) were attributable to cardiovascular causes. In comparison, of the 11 082 patients without a cardiovascular event, 82 (0.7%) died (P < .001). The cumulative incidence of death after an ischemic event among the total randomized study population was 0.5% (0.3% with MI, 0.1% with ST, and 0.1% with ischemic stroke) ( Figure 1) . The cumulative incidence of death for all cardiovascular events, including cardiovascular deaths that were not due to MI, ST, or ischemic stroke, was 1.3%. Death after ST or ischemic stroke primarily occurred within 1 month of presentation, whereas death after MI not related to ST occurred throughout the follow-up period (median survival time, 67.5 days; IQR, 4.0-281.0 days) ( Figure 2 ). Nine ischemic events were immediately fatal, which occurred mainly among patients with ST (n = 8). a For most variables, 0% to 2% of the patients had missing values; however, 7% to 8% of patients were missing data on LVEF.
The unadjusted annualized mortality rate after an ischemic event was 27.2 (95% CI, 20.3-35.7) per 100 person-years. Controlling for demographic characteristics, comorbid conditions, and procedural factors, the occurrence of an ischemic event was associated with a 12.6-fold (95% CI, 9.0-17.6) increased hazard of mortality compared with the absence of such event. Risks of death associated with ST (hazard ratio [HR], 14.6; 95% CI, ) and ischemic stroke (HR, 13.1; 95% CI, 7.2-23.8) were greater in magnitude compared with MI not related to ST (HR, 9.1; 95% CI, 6.1-13.6) ( Table 3) . Risks of death within the first 30 days after an ischemic event and more than 30 days after the event are summarized in eTable 1 in the Supplement.
Incidence and Mortality Risk of Bleeding Events
Among randomized patients, 232 (2.0%) had 235 bleeding events. Of all bleeding events, 155 (66.0%) were moderate, and 80 (34.0%) were severe. Intracranial hemorrhage occurred in 47 of 11 648 (0.4%), of whom 23 (0.4%) were randomized to continued thienopyridine therapy and 24 (0.4%) were randomized to placebo (P = .88).
Patients with bleeding events had lower body mass index, were older, and demonstrated a higher prevalence of cardiovascular risk factors and prior cardiovascular disease (Table 1) . They also had higher rates of prior cancer, were less likely to have initially presented with non-ST-segment elevation MI at the time of PCI, and were more often randomized to continued thienopyridine therapy (140 [60.3%]) than to placebo (92 [39.7%]) (P < .01) ( Table 2) .
The median follow-up time after a bleeding event was 281.5 days (IQR, 98.5-445.0 days). Among 232 patients with a bleeding event, 41 deaths (17.7%) occurred, whereas among 11 416 patients without a bleeding event, 181 deaths (1.6%) occurred (P < .001). Of deaths after a bleeding event, 22 (53.7%) were attributable to cardiovascular causes (9 related to MI, ST, or ischemic stroke). The frequency of death after a moderate bleeding event was 9.7% and after a severe bleeding event was 32.5% ( Figure 1 ). The cumulative incidence of death after a (Figure 2) , with a median survival time of 16.0 days (IQR, 3.0-81.0 days). Three of the 235 bleeding events were immediately fatal. The unadjusted annualized mortality rate after a moderate or severe bleeding event was 21.5 (95% CI, 15.4-29.1) per 100 person-years. Controlling for demographic characteristics, comorbid conditions, and procedural factors, a bleeding event was associated with an 18.1-fold (95% CI, 12.6-26.0) increased hazard for death compared with the absence of a bleeding event. There was a greater hazard of death after severe bleeding events (HR, 36.3; 95% CI, 23.3-56.6) compared with moderate (HR, 8.0; 95% CI, 4.7-13.7) bleeding events. Similar results were obtained when applying BARC bleeding definitions (Table 3) . Risks of death within the first 30 days after a bleeding event and more than 30 days after the event are summarized in eTable 1 in the Supplement.
Incidence and Mortality Risk Among Patients With Multiple Ischemic or Bleeding Events
Among randomized patients, 101 (0.9%) had multiple events, whereas 558 (4.8%) had a single event. Of those with multiple events, 41 (0.4%) had more than 1 ischemic event, 9 (0.1%) had more than 1 bleeding event, and 51 (0.4%) experienced both ischemic and bleeding events. Among patients with both events, 24 (47.1%) had an ischemic event first, 14 (27.4%) had a bleeding event first, and 13 (25.5%) had both ischemic and bleeding events at the time of presentation. Patients with multiple events had a mortality rate of 23.8% compared with 9.3% among those with a single event (P < .01). Mortality among patients with more than 1 ischemic event was 12.2%, among those with more than 1 bleeding event was 22.2%, and among those with both ischemic and bleeding events was 33.3%.
Discussion
This post hoc analysis of randomized patients from the DAPT Study is the largest to date to examine the incidence and prognosis of very late ischemic and bleeding events after coronary stenting. From this analysis, we note the following observations. Among treatment-adherent patients who were event free for 1 year after coronary stenting, ischemic and bleeding events occurring between 12 and 33 months were associated with high risk of mortality. Ischemic events were more common than bleeding events, and death after either category of event accounted for an elevated mortality risk (27.2 deaths for ischemic events and 21.5 deaths for bleeding events per 100 person-years of follow-up, respectively). The risk of death after MI not related to ST was sustained throughout follow-up, whereas the mortality risk after bleeding events was greatest within 30 days of the event. A minority of randomized patients (0.9%) experienced more than 1 ischemic or bleeding event, and mortality was increased among patients with multiple events compared with a single event (23.8% vs 9.3%). The most common cause of death after an ischemic event or a bleeding event was cardiovascular. Overall, the cumulative incidence of death after an ischemic event was 0.5%, and the cumulative incidence of death after a bleeding event was 0.3%. the index procedure, 22 randomization was limited to those patients who were treatment adherent and event free during the first year of follow-up. Despite this restriction, it is noteworthy that ischemic and bleeding events occurring beyond 1 year were associated with substantial mortality risk.
We observed a ratio of ischemic events to bleeding events of 2.1:1 and a ratio of MIs to bleeding events of 1.3:1. These findings are similar to the ratio of events that occurred among this study population in the first 12 months after enrollment in the DAPT Study. 8 Other studies 7, 11 examining late events after MI or PCI have found comparable ratios of cardiovascular events to bleeding events, whereas analyses that included earlier events have demonstrated higher rates of bleeding. 13 Prior analyses have also demonstrated that cardiovascular and bleeding events may differ depending on the timing of initiation of dual antiplatelet therapy.
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In our analysis, very late ischemic events and very late bleeding events were associated with high hazards of mortality, even after adjusting for measured patient factors. Significant mortality risks have been similarly observed for events occurring earlier after PCI. [11] [12] [13] 24, 25 Moderate bleeding, the most frequent bleeding event in the present study, was associated with a risk of mortality similar to that of MI as seen in prior analyses 11, 25 and had mortality risks comparable to those events occurring around the time of the procedure 10 and within the first year after PCI. 12 Conversely, severe (including fatal) bleeding occurred less commonly herein but was associated with a grave risk of death. Patients infrequently experienced ICH (0.4%), and rates of events occurred equally between randomized groups. Of all ischemic events, MI not related to ST occurred most commonly and was associated with a sustained risk of death throughout the study period. This result differed from bleeding events, which were primarily followed by death within 1 month. These temporal relationships are the inverse of those seen in a prior analysis that involved earlier events after acute coronary syndromes. 26 We hypothesize that these disparate findings are largely because of differing types of events. Bleeding events in the present analysis were mainly nonprocedurerelated spontaneous bleeds, which have been associated with higher short-term mortality compared with procedurerelated bleeding. 24 Spontaneous MIs unrelated to the stented artery constituted most ischemic events in our study rather than periprocedural or ST-related MIs. Unlike spontaneous MIs, ST was associated with immediate mortality risk. The sustained risk associated with spontaneous MI may occur via the development of risk factors for future mortality, such as left ventricular dysfunction and arrhythmias, 11 risks expected to persist beyond the time frame of the present study. Few patients had both ischemic and bleeding events, which highlights the need to adapt dual antiplatelet therapy duration according to individual patient characteristics. A prediction rule for patient benefit and harm has been developed from the present study population 27 and may be useful in optimizing care for individual patients.
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Strengths and Limitations
This analysis has several strengths. It included patients with a range of comorbidities and procedural complexity. In addition, all events and outcomes were independently adjudicated. However, the results must also be interpreted in the context of the study design. Patients with a history of significant bleeding or treated with oral anticoagulation were excluded. While ischemic events were more common than bleeding events in the first year as reasons for exclusion from randomization, our analysis is only relevant to determining the prognosis after late events occurring among treatment-adherent patients who have survived event free in the first 12 months after coronary stenting. Fortunately, most patients undergoing PCI have excellent outcomes, without ischemic or bleeding events, recurrent procedures, or treatment nonadherence during the first year of follow-up. 29 In addition, the incidences of ischemic and bleeding events depend on the definitions used. We found similar risks of mortality whether using GUSTO 19 or BARC 20 definitions for bleeding events in that more severe events were associated with higher mortality and less severe events were associated with less subsequent mortality. We excluded cardiovascular deaths not adjudicated to be preceded by MI, ST, or ischemic stroke and, in doing so, excluded 40 sudden cardiac deaths from classification as ischemic events in this study. While it is possible that many of these events were related to ischemia in the absence of documented MI or ST, their exclusion provides a conservative estimate of the proportion and number of ischemic events.
Conclusions
Among patients who survived to 12 months after coronary stenting event free, ischemic events were more frequent than bleeding events, yet both events were associated with high risk of mortality. The risk of death after very late MIs was sustained, whereas death after bleeding events primarily occurred within 30 days. These findings emphasize the need to adapt therapy to individual patient characteristics to avoid very late ischemic and bleeding events among patients after coronary stenting. a Adjusted models were stratified by propensity score quintile. Propensity scores were derived from all variables included in Table 1 and Table 2 .
Role of the Funder/Sponsor: The stent manufacturers who contributed to the funding of the DAPT Study (Abbott Vascular, Boston Scientific, Cordis, and Medtronic) were participating members in the design of the trial, the conduct of the study, and the collection of the data. Specifically, the DAPT Study included patients from each of 4 industry-designed and industry-conducted postmarket studies. The funders had no role in the management, analysis, and interpretation of the data. The Harvard Clinical Research Institute was responsible for the scientific conduct of the DAPT Study and independent analysis of the data. For this substudy, the funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. 
